

In the Claims:

Please rewrite claims 1, 2, 3, 4, 6, 10, 11, 12, 13, 15, 17, 18, 27 and 28 to read as follows:

1. (once amended) A cellular immunogen for immunizing a host against the effects of the product of a target proto-oncogene, the overexpression of which target proto-oncogene is associated with a cancer, which cellular immunogen comprises allogeneic donor cells which have been transfected with at least one transgene construct comprising at least one transgene cognate to the target proto-oncogene and a strong promoter to drive the expression of the transgene in the transfected cells, wherein the transgene is nontransforming and encodes a gene product which induces host immunoreactivity to host self-determinants of the product of the target proto-oncogene gene.

2. (once amended) An immunogen according to claim 1 wherein the transgene comprises:

- A1
- (1) mutant retroviral oncogene DNA; or
 - (2) mutant proto-oncogene DNA of a species different from the host species.

3. (once amended) A cellular immunogen for immunizing a host against the effects of the product of a target proto-oncogene, the overexpression of which target proto-oncogene is associated with a cancer, which cellular immunogen comprises allogeneic donor cells which have been transfected with at least one transgene construct comprising at least one transgene cognate to the target proto-oncogene and a strong promoter to drive the expression of the transgene in the transfected cells, the transgene encoding a gene product which induces host immunoreactivity to host self-determinants of the product of the target proto-oncogene gene, and wherein the transfected cells are non-dividing.

4. (once amended) An immunogen according to claim 3 wherein the transgene comprises mutant retroviral oncogene DNA or mutant proto-oncogene DNA.

A2 6. (once amended) An immunogen according to claim 2 wherein the mutant DNA comprises a deletion mutation in a region of said DNA which is essential for transformation.

10. (once amended) A method for preparing a cellular immunogen for immunizing a host against the effects of the product of a target proto-oncogene, the overexpression of which target proto-oncogene is associated with a cancer, the method comprising:

transfecting allogeneic donor cells with at least one transgene construct comprising at least one transgene cognate to the target proto-oncogene and a strong promoter to drive the expression of the transgene in the transfected cells, wherein the transgene is non-transforming and encodes a gene product which induces host immunoreactivity to host self-determinants of the product of the target proto-oncogene gene.

A3 11. (once amended) A method according to claim 10, wherein the transgene comprises:

- (1) mutant retroviral oncogene DNA; or
- (2) mutant proto-oncogene DNA of a species different from the host species.

12. (once amended) A method for preparing a cellular immunogen for immunizing a host against the effects of the product of a target proto-oncogene, the overexpression of which target proto-oncogene is associated with a cancer, the method comprising:

transfecting allogeneic donor cells with at least one transgene construct comprising at least one transgene cognate to the target proto-oncogene and a strong promoter to drive the expression of the transgene in the transfected cells, the transgene encoding a gene product which induces host immunoreactivity to host self-determinants of the product of the target proto-oncogene gene, wherein the transfected cells are non-dividing.

A3 13. (once amended) A method according to claim 12 wherein the transgene comprises mutant retroviral oncogene DNA or mutant proto-oncogene DNA.

A4 15. (once amended) A method according to claim 11 wherein the mutant DNA comprises a deletion mutation in a region of said DNA which is essential for transformation

A5 17. A method according to claim 10 wherein the transgene is cognate to a target proto-oncogene selected from the group of proto-oncogenes consisting of AKT-2, *c-erbB-2*, MDM-2, *c-myc*, *c-myb*, *c-ras*, *c-src* and *c-yes*.

18. (once amended) A method according to claim 10, wherein the donor cells comprise fibroblasts or bone marrow-derived antigen-presenting cells.

27. (once amended) A method according to claim 19 wherein the donor host cells comprise fibroblasts or bone marrow-derived antigen-presenting cells.

28. (once amended) A method of vaccinating a host against a disease associated with the overexpression of a targeted proto-oncogene comprising

A6 (a) transfecting allogeneic donor cells with at least one transgene construct comprising at least one transgene and a strong promoter to drive the expression of the transgene in the transfected cells, wherein the transgene comprises:

(1) wild-type or mutant cognate retroviral oncogene DNA;
or

(2) wild-type or mutant cognate proto-oncogene DNA of a species different from the host species; and

(b) inserting the cells transfected with the transgene construct into the body of the host to obtain expression of the transgene in the host.

Please add the following new claims:

29. (new) A cellular immunogen for immunizing a host against the effects of the product of a target proto-oncogene, the overexpression of which target proto-oncogene is associated with a cancer, which cellular immunogen comprises allogeneic donor cells which have been transfected with at least one transgene construct comprising at least one transgene cognate to the target proto-oncogene and a strong promoter to drive expression of the transgene in the transfected cells, wherein the transgene is selected from the group consisting of AKT-2, c *erbB*-2, *mdm*-2, c-*myb*, c-*myc*, c-*ras* and c-*yes*, and wherein the transgene encodes a gene product which induces host immunoreactivity to host self-determinants of the product of a target proto-oncogene.

A7 30. (new) A cellular immunogen according to claim 29 wherein the transfected cells are rendered non-dividing.

31. (new) A cellular immunogen according to claim 29 wherein the host cells comprise fibroblasts.

32. (new) A cellular immunogen according to claim 29 wherein the donor host cells comprise fibroblasts or bone marrow-derived antigen-presenting cells

33. (new) A cellular immunogen according to claim 32 wherein the bone marrow-derived antigen-presenting cells are selected from the group consisting of macrophages, dendritic cells, and Langerhans cells.

34. (new) A cellular immunogen according to claim 9 wherein the bone marrow-derived antigen-presenting cells are selected from the group consisting of macrophages, dendritic cells, and Langerhans cells.

35. (new) A method according to claim 18 wherein the bone marrow-derived antigen-presenting cells are selected from the group consisting of macrophages, dendritic cells, and Langerhans cells.

36. (new) A method according to claim 27 wherein the bone marrow-derived antigen-presenting cells are selected from the group consisting of macrophages, dendritic cells, and Langerhans cells.

A7
37. (new) An immunogen according to claim 3 wherein the transgene comprises
(1) wild-type or mutant retroviral oncogene DNA; or
(2) wild-type or mutant proto-oncogene DNA of a species
different from the host species.

38. (new) A method according to claim 12 wherein the transgene comprises
(1) wild-type or mutant retroviral oncogene DNA; or
(2) wild-type or mutant proto-oncogene DNA of a species
different from the host species.

Remarks

Claims 1-28 are pending in the application. Claims 1, 2, 3, 4, 6, 10, 11, 12, 13, 15, 17, 18, 27 and 28 have been amended. Support for amended claims 1, 10 is found on pg. 27, lns. 9-11 of the specification, and support for amended claims 2, 12 is found in originally filed claims 1 and 10, respectively. A "marked up" version of the amended claims is included herein as Appendix A, as required by 37 C.F.R. 1.121(c)(1)(ii).

New claims 29-38 have been added. Support for new claims 29 and 30 is found, respectively, on pg. 27, lns. 7-8 and Table I, and on pg. 32, lns. 13-16 of the specification. Support for new claims 31-36 is found on pg. 38, ln. 20 to pg. 39, ln. 3 of the specification. Support for new claims 37 and 38 is found in originally filed claims 2 and 11, respectively.